Emergency Use of Tocilizumab in Moderate and Severe COVID-19 Patients over the Prevaccination Stage during the Pandemic in Mexico.

Yessica Bernal LunaAlejandro Esquivel LozaJose de Jesus Garduno Garcia

Published in: Advances in virology (2022)

The use of this drug benefits mainly young nonhypertensive patients with a moderate disease and preserved renal functions with no need for invasive respiratory support, regardless of other comorbidities.

Keyphrases

sars cov
high intensity
coronavirus disease
rheumatoid arthritis
emergency department
public health
healthcare
early onset
juvenile idiopathic arthritis
rheumatoid arthritis patients
middle aged
adverse drug